drugset / Trial / NCT04951115
A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study is for subjects with untreated Stage IV small cell lung cancer. Subjects will be given radiation therapy for five days, followed by standard of care chemo-immunotherapy (etoposide + carboplatin or cisplatin + durvalumab) for 4 cycles. Subjects may continue to receive durvalumab after 4 cycles have been completed until disease progression.
Timeline
- Start
- 2021-07-12
- Primary completion
- 2024-01-17
- Completion
- 2024-01-17
Outcome
Outcome not reported
Stopped (Enrollment): “The study was terminated early due to low accrual.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 5 unknown | — |
| Subject | Carboplatin | Small molecule | 6 unknown | — |
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Subject | Cisplatin | Other / unclassified | 80 mg/m2 | — |
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | — |
| Subject | Etoposide | Small molecule | 80 mg/m2 | — |
| Subject | Etoposide | Small molecule | 100 mg/m2 | — |